Last reviewed · How we verify
CDP 6038 SC
At a glance
| Generic name | CDP 6038 SC |
|---|---|
| Sponsor | UCB Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate (PHASE1, PHASE2)
- Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy (PHASE2)
- The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis (PHASE2)
- Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056 (PHASE2)
- The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |